



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION

Clone ID	1G1
Target	SN38
Synonyms	N.A.
Host Species	Rabbit
Description	Biotinylated Anti-SN38 antibody(1G1); Rabbit mAb
Delivery	2-3 weeks
Uniprot ID	N.A.
IgG type	Rabbit IgG
Clonality	Monoclonal
Reactivity	N.A.
Applications	ELISA
Recommended Dilutions	ELISA 1:5000-10000
Purification	Purified from cell culture supernatant by affinity chromatography
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	SN38, a potent chemotherapeutic derived from irinotecan, plays a pivotal role in colorectal cancer treatment. As the active form of irinotecan, SN38 operates as an effective DNA topoisomerase I inhibitor, inducing cell death in cancer cells. Notably, SN38's potential is harnessed in Antibody-Drug Conjugates (ADCs), where it is delivered to tumor sites through innovative methods like liposomes and nanoparticles. This targeted approach enhances SN38's efficacy, emphasizing its crucial role in ADC-based strategies for precise and potent colorectal cancer therapy.
Usage	Research use only
Conjugate	Biotinylated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

